Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0112)
Name
Puerarin
Synonyms
Puerarin; 3681-99-0; Kakonein; Daidzein-8-C-glucoside; 7-hydroxy-3-(4-hydroxyphenyl)-8-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one; Puerarin 80 mm; CHEBI:8633; NPI 031G; Daidzein 8-c-glucoside; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; NSC-380711; Z9W8997416; Puerarin, analytical standard; AC1NQZ4N; MFCD00063399; 8-C-glucoside; 8-Glucosyldaidzein; UNII-Z9W8997416; NSC 380711; 7,4'-Dihydroxy-8-C-glucosylisoflavone; BRN 0064198; 8-Glucopyranosyldaidzein; PUERARIN [INCI]; PUERARIN [WHO-DD]; SureCN8581666; 4-19-00-03200 (Beilstein Handbook Reference); MLS002473178; BIDD:ER0101; CHEMBL486386; SCHEMBL8581666; GTPL12553; HKEAFJYKMMKDOR-VPRICQMDSA-; DTXSID30958020; HKEAFJYKMMKDOR-VPRICQMDSA-N; HMS2198M10; Puerarin, >=98.0% (HPLC); HY-N0145; BDBM50129558; 8-beta-D-Glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AKOS007930376; AKOS015965556; CS-6158; DB12290; KS-5191; 4H-1-Benzopyran-4-one, 8-beta-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; AC-20294; SMR001397270; 4',7-DIHYDROXY-8-C-GLUCOSYLISOFLAVONE; Q63408673; Z1494829516; (1S)-1,5-Anhydro-1-[7-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-D-glucitol; 4H-1-BENZOPYRAN-4-ONE, 8-.BETA.-D-GLUCOPYRANOSYL-7-HYDROXY-3-(4-HYDROXYPHENYL)-; 8-(-bet.-D-Glucopyranosyl-7-hydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one; 8-(beta-D-Glucopyranosyl-7-hydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one; (1S)-1,5-anhydro-1-[7-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-8-yl]-D-glucitol; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; InChI=1/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1

    Click to Show/Hide
Status
Phase 2
Drug Type
Small molecular drug
Structure
Formula
C21H20O9
IUPAC Name
7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
Canonical SMILES
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O
InChI
InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1
InChIKey
HKEAFJYKMMKDOR-VPRICQMDSA-N
PubChem CID
5281807
TTD Drug ID
D0I7MT
Full List of Ferroptosis Target Related to This Drug
NADPH oxidase 4 (NOX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Congestive heart failure ICD-11: BD10
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
Male Sprague Dawley ratsweighing 80-100 g were used to make the HF model induced by descending aortic banding (AB) procedure. Rats receiving a similar procedure except for the arterial ligation were defined as the sham-operated (SO) group. After the procedure, echocardiography was immediately applied to confirm the arterial banding. Rats receiving subcutaneous injections of low- or high-dose puerarin (100 mg/kg/day and 200 mg/kg/day, respectively) after the AB procedure were respectively defined as the Pue1 and Pue2 groups. An equal volume of normal saline was injected into the rats of the SO and AB groups.

    Click to Show/Hide
Response regulation Ferroptosis is involved in the loss of myocytes during heart failure. Puerarin exerted protective effects against heart failure through inhibition of ferroptosis. And puerarin exerted protective effects against heart failure through inhibition of ferroptosis. Regulation of Nox4 signaling might be involved in puerarin inhibiting ferroptosis.
References
Ref 1 Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. Biochem Biophys Res Commun. 2018 Feb 26;497(1):233-240. doi: 10.1016/j.bbrc.2018.02.061. Epub 2018 Feb 8.